Wave Life Sciences is developing a new weight loss candidate, WVE-007, which it believes could not only avoid muscle-loss problems but also the loss of pleasure in eating that some patients report when taking GLP-1 agonists.
Known medically as anhedonia, the adverse event is not listed in the official prescribing information for Novo Nordisk’s semaglutide products and Eli Lilly’s tirzepatide brands, but has become widely reported on social
Key Takeaways
- Wave has promising data from its Duchenne muscular dystrophy and AATD rare disease candidates, but a successful obesity drug would transform the company's fortunes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
